Concepedia

GAIL WAKEFIELD

GW

Statistics

Publications

8

Citations

340

H-Index

8

Active since

1986

Affiliations

Vanderbilt University(Current)

Salk Institute for Biological Studies

GAIL WAKEFIELD is an author at Vanderbilt University specializing in pharmacology, medicine, and reproductive endocrinology.

Publications per year

1986–1997

8

Publications

8

Mode of Suppression of Pituitary and Gonadal Function After Acute or Prolonged Administration of a Luteinizing Hormone-Releasing Hormone Antagonist in Normal Men*

SPYROS N. PAVLOU, GAIL WAKEFIELD, Nicole Schlechter et al. · The Journal of Clinical Endocrinology & Metabolism · 1989 · 74 citations

Medicine, Endocrinology, Pharmacology +17

Suppression of Pituitary-Gonadal Function by a Potent New Luteinizing Hormone-Releasing Hormone Antagonist in Normal Men*

SPYROS N. PAVLOU, GAIL WAKEFIELD, Donald P. Island et al. · The Journal of Clinical Endocrinology & Metabolism · 1987 · 66 citations

Medicine, Endocrinology, Pharmacology +17

Single Subcutaneous Doses of a Luteinizing Hormone-Releasing Hormone Antagonist Suppress Serum Gonadotropin and Testosterone Levels in Normal Men*

SPYROS N. PAVLOU, ROWAN C. DEBOLD, Donald P. Island et al. · The Journal of Clinical Endocrinology & Metabolism · 1986 · 58 citations

Medicine, Endocrinology, Pharmacology +16

Phase I study of the antineovascularization drug CM101.

Russell F. DeVore, Carl G. Hellerqvist, GAIL WAKEFIELD et al. · PubMed · 1997 · 41 citations

Medicine, Oncology, Pharmacology +14

Soluble E-selectin in cancer patients as a marker of the therapeutic efficacy of CM101, a tumor-inhibiting anti-neovascularization agent, evaluated in phase I clinical trial

Barbara D. Wamil, Gary B. Thurman, Håkan Sundell et al. · Journal of Cancer Research and Clinical Oncology · 1997 · 29 citations · Full text

Medicine, Oncology, Pharmacology +16

1–5 of 8